Nintedanib is a drug that has been approved by the FDA for some types of Interstitial lung disease (ILD) which have symptoms of shortness of breath, a dry cough, feeling tired and chest discomfort. It is used for types of ILD that cause scarring in the lungs such as idiopathic pulmonary fibrosis (IPF), certain chronic fibrosing interstitial lung diseases (ILDs) and nintedanib helps lung function in people with systemic sclerosis-associated interstitial lung disease.
Nintedanib belongs to a class of drugs known as tyrosine kinase inhibitors, which work by inhibiting specific enzymes involved in the growth and spread of cancer cells or fibrotic tissue.
Removal of impurity standards from API manufacturing is an integral part of drug manufacturing. Toref has specialization in synthesis / supply of pharmacopoeia impurities, process impurities, isolation and identification of unknown impurities of Nintedanib to all pharmaceutical companies globally. All ready-to-ship Nintedanib Impurities are tabulated below:
|Product Name||CAS No.||Molecular Formula|
|Nintedanib Impurity D||708223-17-0||C10H10ClNO3|
|Nintedanib Impurity E||91133-96-9||C11H13NO4|
|Nintedanib Impurity C||N/A||C22H27N5O5|
|Nintedanib Impurity B||1642584-53-9||C10H9NO6|
|Nintedanib Impurity 58||N/A||C14H15NO6|
|Nintedanib Impurity F||N/A||C12H13NO5|
|Nintedanib Impurity G||N/A||C24H31N5O4|
Contact us now for instant quote. We can provide you with research material for nealy every pharmaceutical impurity you want!